Neogen Corp
NASDAQ:NEOG
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.61
20.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Neogen Corp
Neogen Corp
Cost of Revenue
Neogen Corp
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neogen Corp
NASDAQ:NEOG
|
Cost of Revenue
-$460.1m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-13%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Cost of Revenue
-$625.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-3%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Cost of Revenue
-$1.6B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-26%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Cost of Revenue
-$1.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-21%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Cost of Revenue
-$527.2m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-11%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Cost of Revenue
-$705m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-10%
|
|
Neogen Corp
Glance View
Neogen Corp. engages in the development, manufacture, and sale of products dedicated to food and animal safety. The company is headquartered in Lansing, Michigan and currently employs 1,841 full-time employees. The firm operates through two segments: Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits, culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens, and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services. Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants and insecticides.
See Also
What is Neogen Corp's Cost of Revenue?
Cost of Revenue
-460.1m
USD
Based on the financial report for Aug 31, 2024, Neogen Corp's Cost of Revenue amounts to -460.1m USD.
What is Neogen Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-13%
Over the last year, the Cost of Revenue growth was 0%. The average annual Cost of Revenue growth rates for Neogen Corp have been -21% over the past three years , -16% over the past five years , and -13% over the past ten years .
You don't have any saved screeners yet
